Cell & Gene: The Podcast

We love to hear from our listeners. Send us a message.A pioneer and an icon in diabetes research, Camillo Ricordi, M.D., is the Professor of Surgery, Director of Cell Transplant Center and Director Emeritus of the Diabetes Research Institute at the University of Miami Miller School of Medicine, Florida (UM-DRI). He joins Cell & Gene: The Podcast's Erin Harris to discuss the biggest and most troubling challenges facing the treatment of Type 1 Diabetes (T1D). They also discuss the future of cell and organ transplantation in treating T1D as well as the latest innovations in biopreservation. Subscribe to the podcast!Apple | Spotify | YouTube

Dr. Andrew Scharenberg, Umoja Biopharma's CEO, discusses the evolution of in vivo CAR-T cell therapeutics and the advantages of this technology. They also cover Umoja's lentiviral vector development and manufacturing facility, and their goals for the future.

We love to hear from our listeners. Send us a message.The FDA's Center for Biologics Evaluation and Research (CBER)'s Dr. Peter Marks makes his second appearance on Cell & Gene: The Podcast. This time Dr. Marks talks to Host, Erin Harris, about base editing and prime editing and their potential to meet unmet medical need. They discuss what clinical holds say about the FDA’s views on gene editing. They also discuss heritable genome editing.Subscribe to the podcast!Apple | Spotify | YouTube

Lynelle Hoch, SVP at Bristol Myers Squibb, discusses the near-term future of CAR-T therapy, innovations in the CGT sector, and Bristol Myers Squibb's plans in auto-immune diseases. Challenges in treating solid tumors and personal lives of the hosts are also explored.

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Rachel Haurwitz, Ph.D., CEO at Caribou Biosciences joins Host Erin Harris to discuss the evolution of genome editing, its present state, as well as its undeniable potential. They also discuss Caribou's chRDNA genome editing technology and how it differs from CRISPR-Cas9.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.In June 2023, PDA held its Advanced Therapy Medicinal Products Conference in Baltimore, MD. At the conference, Stephan Krause, Ph.D., Executive Director, AS&T, CT Global Quality at Bristol Myers Squibb, sat down with Cell & Gene: The Podcast Host Erin Harris to discuss the event's major themes and topics as well his focus areas for cell therapy in 2023 and beyond.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as the how the CGT sector is benefiting from RNA, AI, and synthetic biology.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.Dr. Andrew Anzalone, Head of the Prime Editing Platform and Scientific Co-Founder of Prime Medicine joins Cell & Gene: The Podcast to talk with Host Erin Harris about prime editing - what it is and why it is a major technological advancement in gene editing. Anzalone explains why prime editing has a broad applicability for different tissue and cell types to be used in different therapeutic applications.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.Glenn Wright, President and CEO of Parenteral Drug Association (PDA), sat down with Cell & Gene: The Podcast's Erin Harris at the 2023 PDA ATMP conference to discuss not only the conference's theme, “Navigating Through CMC Challenges,” but also Wright's take on CGT manufacturing strategy based on his years in industry. Wright shares his insight on the past, present, and future of the cell and gene therapy space.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.Dr. Usman "Oz" Azam is CEO of Inspirna now but has spent much of his career in the cell and gene therapy space dedicating years as Novartis’ Global Head of Cell & Gene Therapy, President and CEO of Tmunity Therapeutics, and more. Given Oz’s tenure in cell and gene therapy space, I invited him to Cell & Gene: The Podcast to get his valuable take on the state of the space. During our discussion, we cover best practices in engaging with the FDA, the potential in solid tumor cancer treatment, the biggest yet solvable hurdles facing the sector today, and much more.Subscribe to the podcast!Apple | Spotify | YouTube